Construction of a prognostic model of acute myeloid leukemia associated with immunogenic cell death

References

• Smyth MJ, Dunn GP, D R. Schreiber.Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006 90:1–50. doi:10.1016/S0065-2776(06)90001-7.
   PubMed Web of Science ®Google Scholar
• RD S, LJ O, MJ S. Cancer immunoediting: integrating immunity’s roles in cancer suppression and. Science. 2011 Mar 25;331(6024):1565–70. DOI:10.1126/science.1203486.
   PubMed Web of Science ®Google Scholar
• Sautès-Fridman C, Id O, Petitprez F, et al. Tertiary lymphoid structures in the era of cancer immunotherapy. . Nat Rev Cancer. 2019 Jun;19(6):p. 307–325. DOI: 10.1038/s41568-019-0144-6.2019
   Google Scholar
• Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee. Cell Death Differ. 2018 Mar;25(3):486–541. DOI:10.1038/s41418-017-0012-4.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012 Dec;12(12):860–75. DOI:10.1038/nrc3380.
   PubMed Web of Science ®Google Scholar
• Nagata S, Tanaka M -. Programmed cell death and the immune system. Nat Rev Immunol. 2017 May;17(5):333–340. DOI:10.1038/nri.2016.153.
   PubMed Web of Science ®Google Scholar
• Fucikova J, Moserova I, Urbanova L, et al. Prognostic and predictive value of DAMPs and DAMP-Associated processes in cancer. Front Immunol. 2015 6;402. DOI:10.3389/fimmu.2015.00402
   Google Scholar
• Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72.
   PubMed Web of Science ®Google Scholar
• Fucikova J, Kepp O, Kasikova L, et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Amp Dis. 2020 Nov 26;11:1013.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di CV, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of. Lancet. 2018 Mar 17;391(10125):1023–1075. DOI:10.1016/S0140-6736(17)33326-3.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019 Jul;36:70–87. DOI:10.1016/j.blre.2019.04.005.
   PubMed Web of Science ®Google Scholar
• Fucikova J, Truxova I, Hensler M, et al. Calreticulin exposure by malignant blasts correlates with robust anticancer. Blood. 2016 Dec 29;128(26):3113–3124. DOI:10.1182/blood-2016-08-731737.
   PubMed Web of Science ®Google Scholar
• Fucikova J, Kralikova P, Fialova A, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune. Cancer Res. 2011 Jul 15;71(14):4821–33. DOI:10.1158/0008-5472.CAN-11-0950.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yu X, Wang Z, et al. Anthracyclines potentiate anti-tumor immunity: a new opportunity for. Cancer Lett. 2015 Dec 28;369(2):331–5. DOI:10.1016/j.canlet.2015.10.002.
   PubMed Web of Science ®Google Scholar
• Ocadlikova D, Iannarone C, Id O, et al. A screening of antineoplastic drugs for acute myeloid leukemia reveals. Int J Mol Sci. 2020 Sep 16;21(18):6802. DOI:10.3390/ijms21186802.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer. Cancer Cell. 2015 Dec 14;28(6):690–714. DOI:10.1016/j.ccell.2015.10.012.
   PubMed Web of Science ®Google Scholar
• Curran EK, Godfrey J, Kline J -. Mechanisms of immune tolerance in leukemia and lymphoma. Trends Immunol. 2017 Jul;38(7):513–525. DOI:10.1016/j.it.2017.04.004.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray. Nucleic Acids Res. 2015 Apr 20;43(7):e47. DOI:10.1093/nar/gkv007.
   PubMed Web of Science ®Google Scholar
• Newman AM, Orcid I, Steen CB, et al. Determining cell type abundance and expression from bulk tissues with digital. Nat Biotechnol. 2019 Jul;37(7):773–782. DOI:10.1038/s41587-019-0114-2.
   PubMed Web of Science ®Google Scholar
• AD G, De RD, Agostinis P. Immunological metagene signatures derived from immunogenic cancer cell death. Oncoimmunology. 2015 Aug 12;5(2):e1069938.
   PubMedGoogle Scholar
• Tomczak K, Czerwińska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–77.
   PubMedGoogle Scholar
• Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005 202:1691–701. DOI:10.1084/jem.20050915.
   Google Scholar
• Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of. J Immunother Cancer. 2020 Mar;8(1):e000337. DOI:10.1136/jitc-2019-000337.
   PubMed Web of Science ®Google Scholar
• Yousefi H, Yuan J, Keshavarz-Fathi M, et al. Immunotherapy of cancers comes of age. Expert Rev Clin Immunol. 2017 Oct;13(10):1001–1015.
   PubMed Web of Science ®Google Scholar
• Busato D, Mossenta M, Baboci L, et al. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Rev Clin Pharmacol. 2019 May;12(5):453–470.
   PubMed Web of Science ®Google Scholar
• Morandi F, Orcid I, Frassoni F, et al. Novel immunotherapeutic approaches for neuroblastoma and malignant melanoma. J Immunol Res. 2018 Oct 30;2018:8097398. DOI:10.1155/2018/8097398.
   PubMed Web of Science ®Google Scholar
• Garg AD, Galluzzi L, Apetoh L, et al. Molecular and translational classifications of damps in immunogenic cell death. Front Immunol. 2015 Nov 20;6:588. DOI:10.3389/fimmu.2015.00588.
   PubMed Web of Science ®Google Scholar
• Linkermann A, Stockwell BR, Krautwald S, et al. Regulated cell death and inflammation: an auto-amplification loop causes organ. Nat Rev Immunol. 2014 NovOct;14(11):759–67. [Epub 2014 17.2014]. DOI:10.1038/nri3743
   PubMed Web of Science ®Google Scholar